They neither support the putative function of LATS proteins as tumor suppressors nor are they consistent with the previous study of ovarian cancer patients, where elevated LATS1 and LATS2 expression was associated with better outcome in serous ovarian cancer patients (Xu et al. 2015). Here, LATS1 is linked to ovarian serous adenocarcinoma.